OKUR vs OKTA: Which is Better to Buy in 2026?

Side-by-side fundamental comparison based on AI analysis of SEC filings

AI Verdict

OKTA has stronger fundamentals based on our AI analysis.

OKUR
OnKure Therapeutics, Inc.
SELL
75%
Confidence
VS
OKTA
Okta, Inc.
HOLD
72%
Confidence

OKUR vs OKTA Fundamental Comparison

Metric OKUR OKTA
Revenue $3.4M $2.9B
Net Income $-59.5M $235.0M
Net Margin -1,733.7% 8.1%
ROE -105.9% 3.4%
ROA -95.8% 2.4%
Current Ratio 10.28x 1.43x
Debt/Equity 0.00x 0.00x
EPS $-4.40 $1.31

Green = Better metric | Red = Weaker metric

View Full OKUR Analysis →
View Full OKTA Analysis →
Browse Sectors: Technology Healthcare Finance Energy Consumer Industrial
Stock Lists: Strong Buy Undervalued Growth Dividend

You Might Also Compare

OKUR vs AAPL OKTA vs MSFT OKUR vs GOOGL OKTA vs AMZN

OKUR vs OKTA: Frequently Asked Questions

Is OKUR or OKTA a better buy in 2026?

Based on dual AI fundamental analysis (Claude and ChatGPT), OKTA has stronger fundamentals. OKUR is rated SELL (75% confidence) while OKTA is rated HOLD (72% confidence). This is not investment advice.

How does OKUR compare to OKTA fundamentally?

OnKure Therapeutics, Inc. has ROE of -105.9% vs Okta, Inc.'s 3.4%. Net margins are -1,733.7% vs 8.1% respectively.

Which stock pays higher dividends, OKUR or OKTA?

OKUR has a dividend yield of N/A or no dividend while OKTA has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.

Should I invest in OKUR or OKTA for long term?

For long-term investing, consider that OKUR has SELL rating with 75% confidence, while OKTA has HOLD rating with 72% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.

What do the AI models say about OKUR vs OKTA?

Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For OKUR vs OKTA, the AI consensus favors OKTA based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.